secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001104659-24-059101
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood Q1 revenue down 28% YoY, net loss $4.2M; apraglutide Phase III positive
--------------------------------------------------------------------------------

- Q1 total revenue $74.9M vs $104.1M YoY; GAAP net loss of $4.2M vs net income of $45.7M.
- LINZESS prescription demand grew 10% YoY; revenue impacted by gross-to-net change.
- Positive Phase III STARS trial of apraglutide in SBS-IF; NDA filing planned.
- Revised FY 2024 guidance due to LINZESS gross-to-net change estimate.
- Adjusted EBITDA fell to $12.8M from $60.4M YoY; non-GAAP net loss per share $(0.02).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465924059101/0001104659-24-059101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465924059101/tm2413858d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-059101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer